C. difficile control set, 10/14
October 2014—SeraCare Life Sciences announced the launch of its Accurun 501 C. difficile Control, the company’s first molecular control product targeting hospital-acquired infections.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
SeraCare Life Sciences
Hepatitis C, Chagas, and dengue research panels, 8/14
August 2014—SeraCare Life Sciences released four research panels that deliver hard-to-find material for hepatitis C, Chagas, and dengue.
SeraCare expands genetic portfolio, 6/14
June 2014—SeraCare launched its Accurun 611 product, a reference material that provides heterozygous, mutant, or wild-type scores for Factor II, Factor V, and Methlyenetetrahydrofolate reductase.
CMV DNA linearity panel, 4/14
April 2014—SeraCare Life Sciences is offering a nine-member panel made from serial dilutions of a cultured virus with established reactivity for CMV DNA called the CMV DNA AccuSpan Linearity Panel.
SeraCare acquires KPL, 10/13
SeraCare Life Sciences has acquired Kirkegaard & Perry Laboratories (KPL), a provider of antibodies and related reagents for the diagnostic and life sciences markets.
Anti-Toxoplasma performance panel, 9/13
SeraCare Life Sciences has introduced a new AccuSet anti-Toxoplasma performance panel.
SeraCare Life Sciences goes live with SAP
SeraCare Life Sciences completed its implementation of SAP enterprise resource planning (ERP) software. The SAP system integrates the company’s inventory planning and control, purchasing, production management, quality management, and financial reporting systems into a single software solution.
Anti-herpes, HCV panels, 7/13:107
SeraCare Life Sciences offers three new Accuvert seroconversion panels and one new Accuset performance panel. The new Accuvert seroconversion panels are HCV seroconversion panel PHV924, providing undiluted plasma samples from a single male donor of genotype 2b, drawn over an 88-day period in 2008; HCV seroconversion panel PHV925, providing undiluted plasma samples from a single male donor of genotype 1a, drawn over a 27-day period in 2008; and HCV seroconversion panel PHV926, providing undiluted plasma samples from a single male donor of genotype 3a, drawn over a 14-day period in 2009.
Seroconversion panels for HBV and HIV, 5/13:86
SeraCare Life Sciences has launched three seroconversion panels that provide difficult-to-find patient samples for hepatitis B and HIV. HBV seroconversion panel PHM938 comprises six undiluted plasma samples from a single donor drawn over a six-day period and is HBV DNA-positive from the first bleed.